Q1 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Teva Pharmaceutical Industries Ltd (TEVA) reported its ninth consecutive quarter of growth, with revenue up 5% to $3.9 billion.
- Innovative brands AUSTEDO, AJOVY, and UZEDY showed strong performance, with AUSTEDO growing 39% globally.
- The company is on track to achieve a 30% operating margin by 2027, driven by cost optimization and strategic capital allocation.
- Teva's Biosimilar business is expanding, with two new products launched in the US and more expected by 2027.
- The company is transforming from a pure-play Generics company to a leading biopharmaceutical company, focusing on innovative products and pipeline development.
- The Generic business growth slowed to 3% due to prior comparisons and inflationary slowdowns in international and European markets.
- Teva faces potential challenges from US tariffs, although they have been absorbed in the 2025 guidance.
- The company anticipates a revenue cliff from Generic Revlimid in 2026, which may impact financial performance.
- Net debt increased by $500 million due to cash distribution related to the Japan business closure and exchange rate fluctuations.
- There is uncertainty regarding the impact of new US tariffs and the potential need for governmental subsidies to mitigate cost increases.
Hello, and welcome to the Q1 2025 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex, and I'll be coordinating the call today. (Operator Instructions).
I'll now hand it over to your host, Christopher Stevo, Head of Investor Relations to begin. Please go ahead.
Thank you, Alex. Good morning everyone. In the course of this call, we are going to be making some forward-looking statements and any statements we make regard only as of today and we undertake no obligation to update them in the future. And if you have any additional questions on our forward-looking statements, you can see the relevant sections of our SEC filings and our Forms 10-K and 10-Q.
Additionally, during todayâs call all comments made to revenue growth year-over-year will be in local currency terms unless otherwise noted by one of us. And with that I will turn it over to Richard Francis.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
